Login With Google
ILS develops antibodies against Chikungunya infection
Why is it in news?
- The Institute of Life Sciences (ILS), which functions under the Department of Biotechnology, has entered into a non-exclusive license for product commercialisation after having successfully developed antibodies against the Chikungunya viral (CHIKV) infection.
More in news
- Development of antibodies:
- The antibodies were developed following decade-long research on the CHIKV infection at the ILS laboratory.
- The ILS will partner with a biotechnology-based company for product commercialisation and marketing of antibodies in a 60:40 profit sharing basis.
- Significant impact:
- Generation of antibodies has had significant impact on the progress of CHIKV-based research.
- It will help researchers unravel myriad aspects of virus pathogenesis.
- Developing antivirals against Chikungunya virus:
- With greater light shed upon the CHIKV infection biology using these antibodies, research communities are now a step closer to developing efficacious antivirals and other control strategies against the Chikungunya virus.
- Lack of information: The molecular virologist, who has 20 years of experience in the field, started working on this aspect as there was hardly any information on the basic mechanisms underlying CHIKV virus infection and pathogenesis.
Source
The Hindu